Prana Biotechnology’s PBT2 Trial Provides Further Data On Treating Alzheimer’s Disease

Prana Biotechnology’s PBT2 Trial Provides Further Data On Treating Alzheimer’s Disease
Alzheimer's researchRecent results from Prana Biotechnology's IMAGINE Alzheimer's trial, released earlier this year (March), as well as the company's ongoing sub-analysis, has suggested to the company's research team that further analysis of the PiB-PET Standardized Uptake Value Ratio (SUVR) and the tendency towards preservation of brain volume in PBT2 treated patients may be necessary. The results of the ongoing analysis will allow Prana to readjust future trials, explained Dr. Colin Masters, Executive Director at Mental Health Research Institute and professor at the University of Melbourne, who also collaborates with the pharmaceutical industry and biotechnology companies in discovering compounds that can inhibit the production or aggregation of amyloid in an Alzheimer's patient's brain. After the first results of the study suggested the potential benefits of PBT2 in reducing amyloid burden levels, further sub-analyses were performed, including one measuring the effects of a daily dose of 250 mg of PBT2 throughout a year of treatment. This trial managed to enroll 42 patients, 27 who took PBT2 and 15 who took a placebo. The goal of the trial was to determine if amyloid burden would decrease in patients using PBT2 when compared to the group using placebo. The company recently no
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *